Oncogene: combination therapy can significantly delay the growth of malignant brain tumors in children

May 28, 2018 / bioin / - neuroblastoma (MB) is the most common malignant brain tumor in children Myc gene is usually overexpressed, which is closely related to the poor prognosis of MB The bet bromine domain can recognize the acetyl lysine residue, which usually promotes and maintains the transcription of myc gene Some special cyclin dependent kinases (CDKs) can promote the stability of myc gene in cancer cells In order to find a better way to treat MB, scientists from Uppsala University and other institutions, led by Professor Fredrik J swartering, found that the combination of bet bromine domain inhibitor and CDK2 inhibitor targeting myc expression and myc stabilizing factor can inhibit MB cell growth Relevant research results were recently published in oncogene, entitled "combined bet bromodomain and CDK2" The researchers found that this combination therapy can synergize, cause cancer cell division cycle blocked and large-scale apoptosis Using the RNA SEQ method, the researchers characterized the changes in the transcription level of cancer cells caused by this combined myc inhibition method They found that in their MYCN induced group 3 MB animal model, the changes in the transcription level caused by this method were similar to the effects of closing MYCN with doxycycline In addition, the researchers found that the combination therapy significantly prolonged the survival of the orthotopic group 3 MB tumor bearing mice with high myc expression compared to the single therapy Overall, this study suggests that inhibition of both CDK2 and bet bromine domains may be a new approach to myc driven neuroblastoma Reference: Sara Bolin et al Combined bet bromodomain and CDK2 initiation in myc driven medulloblastoma, oncogene (2018) Doi: 10.1038/s41388-018-0135-1